Unknown

Dataset Information

0

The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells.


ABSTRACT: The phosphopeptide P140 issued from the spliceosomal U1-70K snRNP protein is recognized by lupus CD4(+) T cells, transiently abolishes T cell reactivity to other spliceosomal peptides in P140-treated MRL/lpr mice, and ameliorates their clinical features. P140 modulates lupus patients' T cell response ex vivo and is currently included in phase IIb clinical trials. Its underlying mechanism of action remains elusive. Here we show that P140 peptide binds a unique cell-surface receptor, the constitutively-expressed chaperone HSC70 protein, known as a presenting-protein. P140 induces apoptosis of activated MRL/lpr CD4(+) T cells. In P140-treated mice, it increases peripheral blood lymphocyte apoptosis and decreases B cell, activated T cell, and CD4(-)CD8(-)B220(+) T cell counts via a specific mechanism strictly depending on gammadelta T cells. Expression of inflammation-linked genes is rapidly regulated in CD4(+) T cells. This work led us to identify a powerful pathway taken by a newly-designed therapeutic peptide to immunomodulate lupus autoimmunity.

SUBMITTER: Page N 

PROVIDER: S-EPMC2669294 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature

altmetric image

Publications

The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells.

Page Nicolas N   Schall Nicolas N   Strub Jean-Marc JM   Quinternet Marc M   Chaloin Olivier O   Décossas Marion M   Cung Manh Thong MT   Van Dorsselaer Alain A   Briand Jean-Paul JP   Muller Sylviane S  

PloS one 20090423 4


The phosphopeptide P140 issued from the spliceosomal U1-70K snRNP protein is recognized by lupus CD4(+) T cells, transiently abolishes T cell reactivity to other spliceosomal peptides in P140-treated MRL/lpr mice, and ameliorates their clinical features. P140 modulates lupus patients' T cell response ex vivo and is currently included in phase IIb clinical trials. Its underlying mechanism of action remains elusive. Here we show that P140 peptide binds a unique cell-surface receptor, the constitut  ...[more]

Similar Datasets

| S-EPMC9740613 | biostudies-literature
| S-EPMC3091198 | biostudies-literature
| S-EPMC10290117 | biostudies-literature
| S-EPMC5216347 | biostudies-literature
| S-EPMC10624795 | biostudies-literature
| S-EPMC2830701 | biostudies-literature
| S-EPMC9199391 | biostudies-literature
| S-EPMC5459302 | biostudies-literature
| S-EPMC6070662 | biostudies-literature
| S-EPMC7589999 | biostudies-literature